University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Interactions
Database of Antiretroviral Drug Interactions

All Interactions with Tenofovir disoproxil fumarate (Viread)

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Abacavir135
(ABC)(Ziagen)
300 mg BID300 mg QD x 13 daysNo significant changeNo significant change--

No dose adjustment necessary

Adefovir235
(Hepsera)
10 mg QD300 mg QD x 1 dose-No significant change--

No dose adjustment necessary

Atazanavir155
(ATV)(Reyataz)
300 mg QD with 100 mg ritonavir QD x 10 d300 mg QD x 10 d, separated 12 hours away from atazanavir/ritonavirAtazanavir Cmin: decreased 20%Tenofovir AUC: increased 37%; Cmax: increased 34%; Cmin: increased 29%Increased tenofovir effects-

Coadminister atazanavir/ritonavir together with tenofovir

Atazanavir148
(ATV)(Reyataz)
300 mg QD with ritonavir 100 mg QD300 mg QDAtazanavir AUC: no significant change; Cmax: no significant change; Cmin: decreased 21% (compared to atazanavir 300 QD with ritonavir 100 mg QD)Ritonavir AUC: increased 20%; Cmax: no signficant change; Cmin: no significant change--Unknown

No dose adjustment necessary

Atazanavir8, 9, 10
(ATV)(Reyataz)
300 mg QD with ritonavir 100 mg QD on days 1-42300 mg QD on days 15-42Atazanavir Cmax: decreased 28%; AUC: decreased 25%; Cmin: decreased 26%; Ritonavir Cmax: decreased 28%; AUC: decreased 25%; Cmin: no significant changeNot studiedDecreeased atazanavir effects; possibly increased tenofovir effects-

Do not coadminister with unboosted atazanavir (400 mg); Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Atazanavir155
(ATV)(Reyataz)
400 mg QD with 100 mg ritonavir QD x 10 d300 mg QD x 10 dAtazanavir AUC: increased 38%; Cmax: increased 31%; Cmin: increased 33%Tenofovir AUC: increased 55%; Cmax: increased 39%; Cmin: increased 70%Increased atazanavir and tenofovir effects-

Do not coadminister

Atazanavir9, 123, 124,
(ATV)(Reyataz)
400 mg QD with a light meal300 mg QD with a light mealAtazanavir AUC: decreased 26%; Cmax: decreased 24%; Cmin: decreased 40%Tenofovir AUC: increased 25%; Cmax: no significant changeDecreased atazanavir effects; increased tenofovir effectsUnknown

Do not coadminister with unboosted atazanavir (400 mg); Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen

Atazanavir/cobicistat755
(others)(Evotaz)
--Not studied; Potential decreased atazanavir concentrationsNot studied; Potential increased tenofovir concentrations--

Monitor for tenofovir associated adverse effects.

Boceprevir569
(Victrelis)
800 mg TID x 7 days300 mg QD x 7 daysNo significant effectTenofovir Cmax: increased 32%--

No dose adjustment necessary

Buprenorphine443
(Suboxone)(Buprenex)
16 mg QD300 mg QDNo significant change---

No dose adjustment necessary

Daclatasvir747
(Daklinza)
60 mg daily300 mg dailyDaclatasvir AUC increased 10%; Cmin increased 15%---

No dose adjustment necessary

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Darunavir161
(DRV)(Prezista)
300 mg BID with ritonavir 100 mg BID300 mg QDDarunavir AUC: increased 21%; Cmax: increased 16%; Cmin: increased 24%Tenofovir AUC: increased 22%; Cmax: increased 24%; Cmin: increased 37%Possibly increased darunavir effects; possibly increased tenofovir effects-

No dose adjustment necessary

Didanosine143
(ddI)(Videx)
----Potential early virologic failure-

Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients

Didanosine96
(ddI)(Videx)
250 mg or 400 mg (buffered formulation) QD x 7 days300 mg QDDidanosine AUC: increased 44%; Cmax: increased 28%No significant changeIncreased didanosine effectsPossible shared elimination pathway

Reduce didanosine dose to 250 mg QD when used with tenofovir

Didanosine103
(ddI)(Videx)
250 mg QD (enteric coated) x 1 (given with food, without food and staggered by 2 hours)300 mg QD x 9 daysDidanosine AUC: no significant change (fed); Cmax: no significant change; Didanosine AUC: no significant change (staggered); Cmax: no significant change (staggered); Didanosine AUC: no significant change (fed); Cmax: decreased 29% (fed)All values compared to 400 mg QD (enteric coated) reference dose.No significant change-Possible shared elimination pathway

Reduce didanosine dose to 250 mg QD when used with tenofovir

Didanosine97, 96
(ddI)(Videx)
400 mg (buffered formulation) QD x 7 days300 mg QD x 7 daysDidanosine AUC: increased 44%; Cmax: increased 28%No significant changeIncreased didanosine effectsPossible shared elimination pathway

Reduce didanosine dose to 250 mg QD when used with tenofovir

Didanosine96, 102
(ddI)(Videx)
400 mg (enteric coated capsule) x 1 dose300 mg QDDidanosine AUC: increased 48% (fasted); Cmax: increased 48% (fasted)Didanosine AUC: increased 60% (fed); Cmax: increased 64% (fed)No significant changeIncreased didanosine effectsPossible shared elimination pathway

Reduce didanosine dose to 250 mg QD when used with tenofovir

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Didanosine96
(ddI)(Videx)
400 mg QD (enteric coated) x 7 days (given with food)300 mg QD--Increased didanosine effectsPossible shared elimination pathway

Reduce didanosine dose to 250 mg QD when used with tenofovir

Didanosine96
(ddI)(Videx)
400 mg QD (enteric coated) x 7 days (given without food)300 mg QDDidanosine AUC: increased 48%; Cmax: increased 28%Not studiedIncreased didanosine effectsPossible shared elimination pathway

Reduce didanosine dose to 250 mg QD when used with tenofovir

Dolutegravir641
(Tivicay)
50 mg QD300 mg QDNo significant change TDF AUC: increased 12%; Cmin: increased 19%--

No dose adjustment necessary

Efavirenz143
(EFV)(Sustiva)
--- - Potential early virologic failure-

Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients

Efavirenz96, 98
(EFV)(Sustiva)
600 mg QD x 14 days300 mg QD x 7 daysNo significant changeNo significant change--

No dose adjustment necessary

Emtricitabine125, 126
(FTC)(Emtriva)
200 mg QD x 7 days300 mg QD x 7 daysNo significant changeNo significant change--

No dose adjustment necessary

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Emtricitabine96
(FTC)(Emtriva)
200 mg QD x 7 days300 mg QDNo significant changeNo significant change--

No dose adjustment necessary

Entecavir391
(Baraclude)
--No significant changeNo significant change--

No dose adjustment necessary

Ethinyl estradiol/norethindrone acetate367
(others)(Ortho-Novum)
1 tab QD300 mg QDNo significant changeNo significant change--

No dose adjustment necessary

Ethinyl estradiol/norgestimate430
(others)(Ortho Tri-Cyclen, Ortho Tri-Cyclen)
1 tab QD300 mg QDEthinyl estradiol: no significant effect; Deacetyl norgestimate: no significant effect- --

No dose adjustment necessary

Etravirine429
(ETR)(Intelence)
200 mg BID300 mg QDEtravirine AUC: decreased 19%; Cmin: decreased 18%; Cmax: decreased 19%Tenofovir AUC: increased 15%; Cmin: increased 19%; Cmax: increased 15%- -

No dose adjustment necessary

Fosamprenavir153
(FPV)(Lexiva)
1400 mg with 100 mg ritonavir QD x 14 days300 mg QDAmprenavir AUC: no significant change; Cmax: no significant change; Cmin: increased 24%No significant change--

No dose adjustment necessary

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Fosamprenavir153
(FPV)(Lexiva)
1400 mg with 200 mg ritonavir QD x 14 days300 mg QDNo significant changeNo significant change--

No dose adjustment necessary

Indinavir96, 98
(IDV)(Crixivan)
800 mg TID x 7 days300 mg QD x 7 daysNo significant changeNo significant change--

No dose adjustment necessary

Lamivudine96, 97
(3TC)(Epivir)
150 mg BID x 7 days300 mg QD x 7 daysLamivudine Cmax: decreased 24%No significant change- -

No dose adjustment necessary

Ledipasvir/sofosbuvir727, 713
Ledipasvir 90 mg with sofosbuvir 400 mg QD300 mg QD- TDF AUC ↑ 40%-98% when TDF co-administered with rilpivirine and efavirenz. Further ↑ TDF possible if co-administered with protease inhibitors.--

No dose adjustment necessary, consider renal function and avoid use if CrCl <60 ml/min. Monitor for TDF toxicity

Lopinavir/ritonavir96, 98
(LPV/r)(Kaletra)
400 mg/100 mg BID x 14 days300 mg QDLopinavir AUC: decreased 15%; Cmax: decreased 15%; Cmin: no significant change; Ritonavir AUC: decreased 24%; Cmax: decreased 28%; Cmin: no significant changeTenofovir AUC: increased 34%; Cmax: increased 31%; Cmin: increased 29%Increased tenofovir effects-

No dose adjustment necessary

Lopinavir/ritonavir104
(LPV/r)(Kaletra)
400/100 mg BID300 mg QDLopinavir: no significant change. Ritonavir: no significant changeNot studied--

No dose adjustment necessary

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Lopinavir/ritonavir78, 96
(LPV/r)(Kaletra)
400/100 mg BID300 mg QDNo significant changeTenofovir AUC: increased 32%; Cmin: increased 51%; half-life: no significant changePossibly increased tenofovir effects-

No dose adjustment necessary

Methadone185
(Dolophine)
40-110 mg/day300 mg QDNo significant changeNot reported--

No dose adjustment necessary

Methadone96, 188
(Dolophine)
stable dose (range 45-130 mg) QD300 mg QD on days 2-15R-methadone: no significant change;S-methadone: no significant change;total methadone: no significant changeNot studied--

No dose adjustment necessary

Nevirapine143
(NVP)(Viramune)
----Potential early virologic failure-

Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment naive patients

Probenecid96
(Benemid)(Benemid)
- - No significant changeIncreased tenofovir levelsIncreased tenofovir effectsProbenecid-induced inhibition of the renal tubular secretion of tenofovir

Avoid combination

Raltegravir3
(RAL)(Isentress)
400 mg BID300 mg QDRaltegravir AUC: increased 49%; Cmax: increased 64%-Possibly increased raltegravir effects-

No dose adjustment necessary

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Ribavirin235
(Rebetol, Virazole)
800 mg QD300 mg QD x 1 dose-No significant change--

No dose adjustment necessary

Rifampin348, 349
(Rifampicin)(Rifadin)
600 mg QD on days 11-21300 mg QD on days 1-20No significant changeNo significant change--

No dose adjustment necessary

Rilpivirine567
(RPV)(Edurant)
150 mg QD300 mg QDNo significant changeTenofovir AUC: increased 23%; Cmin: increased 24%; Cmax: increased 19%Potentially increased tenofovir effects-

No dose adjustment necessary

Saquinavir149
(SQV)(Fortovase, Invirase)
1000 mg (hard gel caps) with ritonavir 100 mg BID on days 1-14300 mg QD on days 3-14Saquinavir AUC: no significant change; Cmax: no significant change; Cmin: no significant changeRitonavir AUC: no significant change; Cmax: no significant change; Cmin: increased 27%Not studied--

No dose adjustment necessary

Saquinavir142
(SQV)(Fortovase, Invirase)
1000 mg BID with 100 mg ritonavir on days 1-14300 mg QD on days 2-14No significant change either for saquinavir or ritonavirNo significant change--

No dose adjustment necessary

Saquinavir145
(SQV)(Fortovase, Invirase)
1000 mg saquinavir BID with 100 mg ritonavir BID300 mg QDSaquinavir AUC: increased 29%; Cmax: increased 22%; Cmin: incresed 47%Tenofovir Cmin: increased 23%--

No dose adjustment necessary

Coadministered DrugDose of DrugDose of Tenofovir disoproxil fumarateEffect on Drug LevelsEffect on Tenofovir disoproxil fumarate LevelsPotential Clinical EffectsMechanism of InteractionManagement
Simeprevir679
(Olysio)
150 mg QD x 7 days300 mg QD x 7 daysSimeprevir AUC: decreased 24%; Cmax: decreased 15%Tenofovir AUC: increased 18%; Cmax: increased 19%; Cmin: increased 24% --

No dose adjustment necessary

Sofosbuvir659
(Sovaldi)
400 mg x 1300 mg QDSofosbuvir Cmax increased 25%---

No dose adjustment necessary

Stavudine12
(d4T)(Zerit)
100 mg extended release x 1 dose300 mg QD x 7 daysNo significant changeNot studied--

No dose adjustment necessary

Stavudine136
(d4T)(Zerit)
100 mg XR QD on days 1 and 9300 mg QD on days 2-9-No significant change--

No dose adjustment necessary

Telaprevir571
(Incivek)
1125 mg Q8H x 7 days300 mg QD administered with 600 mg efavirenz QD x 7 daysTelaprevir AUC: decreased 18%; Cmin: decreased 25%Tenofovir Cmin: increased 17%; Cmax: increased 22%Possibly increased tenofovir effects-

No dose adjustment necessary

Telaprevir571
(Incivek)
1500 mg Q12H x 7 days300 mg QD administered with efavirenz 600 mg QD x 7 daysTelaprevir AUC: decreased 20%; Cmin: decreased 48%Tenofovir Cmax: increased 24%Potentially decreased telaprevir effects-

Dose adjust telaprevir to 1125 mg Q8H when used with efavirenz.

Telaprevir571
(Incivek)
750 mg Q8H x 7 days300 mg QD x 7 daysNo significant effectTenofovir AUC: increased 30%; Cmin: increased 41%; Cmax: increased 30%Possibly increased tenofovir effects-

Dose adjustment not established

Tipranavir154
(TPV)(Aptivus)
500 mg BID with 100 mg ritonavir BID300 mg x 1 doseTipranavir Cmin: decreased 21%Tenofovir Cmax: decreased 23%--

No dose adjustment necessary

Tipranavir154
(TPV)(Aptivus)
750 mg BID with 200 mg ritonavir BID x 23 doses300 mg x 1 doseNo significant changeTenofovir Cmax: decreased 38%--

No dose adjustment necessary

"-" indicates that there are no data available
 3:Isentress [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; October 2007.
 8:Taburet AM, Piketty C, Gerard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a substudy of Puzzle2-ANRS 107 trial [abstract #537]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.
 9:Data on file. Bristol-Myers Squibb Company. Princeton, NJ.
 10:Taburet A-M, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-96.
 12:Kaul S, Bassi K, Damle B, et al. Lack of interaction between stavudine extended-release formulation and tenofovir disoproxil fumarate [abstract #534]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.
 78:Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005.
 96:Viread [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2006.
 97:Kearney B, Flaherty J, Sayre J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and lamivudine or didanosine [abstract #337]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina.
 98:Flaherty J, Kearney B, Wolf J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir or lopinavir/ritonavir [abstract #336]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina.
 102:Kearney B, Damle B, Plummer A, et al. Pharmacokinetics evaluation of tenofovir DF and enteric-coated didanosine. Sixth International Congress on Drug Therapy in HIV Infection; 2002 November 17-21; Glasgow, United Kingdom.
 103:Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract #533]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.
 104:Poirier J, Meynard J, Guiard-Schmid J, et al. Lack of alteration of lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and tenofovir DF. [abstract #H-1715]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois.
 123:Dear Health Care Provider letter. Bristol-Myers Squibb Co., Aug 8, 2003.
 124:Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract #A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.
 125:Emtriva [package insert]. Foster City, CA: Gilead Sciences, Inc.; Sept 2005.
 126:Blum MR, Begley J, Zong J, et al. Lack of a pharmacokinetic interaction between emtricitabine and tenofovir DF when coadministered to steady state in healthy volunteers [abstract #A-1621]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.
 135:Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF [abstract #A-1615]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.
 136:Kaul S, Bassi K, Damle B, et al. Stavudine extended release formulation and tenofovir disoproxil fumarate: lack of a pharmacokinetic drug interaction [abstract #602]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California.
 142:Boffito M, Back D, Stainsby-Tron M, et al. Tenofovir does not alter the pharmacokinetics os saquinavir hard gel capsule/ritonavir; data from HIV patients [abstract TuPeB4610]. XV International AIDS Conference; 2004 July 11-16; Bangkok, Thailand.
 143:Bristol-Myers Squibb Company. Potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads. Dear Health Care Provider letter. November 2004.
 145:Zong J, Chittick G, Blum MR, et al. Pharmacokinetic assessment of tenofovir DF and ritonavir-boosted saquinavir in healthy subjexts [abstract A-444]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, D.C.
 148:von Hentig N, Haberl A, Lutz T, et al. Concomitant intake of tenofovir disoproxil fumarate does not impair the plasma exposure of ritonavir-boosted atazanavir in HIV-1 infected adults [abstract PI-40]. American Society for Clinical Pharmacology and Therapeutics; 2005 March 2-6; Orlando, Florida.
 149:Boffito M, Back D, Stainsby-Tron M, et al. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1 infected subjects. Br J Clin Pharmacol 2004; 59: 38-42.
 153:Kurowski M, Walli R, Breske A, et al. Coadministration of tenofovir 300 mg QD with fosamprenavir/ritonavir 1400/100 mg QD or 1400/200 mg QD doses not affect amprenavir pharmacokinetics (COL 20081)[abstact #10]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Quebec, Canada.
 154:Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.
 155:Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects [abst. 16]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Canada.
 161:Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; April 2010.
 185:Smith P, Kearney B, Cloen D, et al. Tenofovir DF does not affect the pharmokinetics or pharmacodynamics of methadone [abst 869]. 2nd International Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris, France.
 188:Smith PF, Kearney BP, Liaw S, et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R- and S-methadone. Pharmacother 2004: 24: 970-77.
 235:Kearney BP, Benhamou Y, Flaherty J, et al. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis [abstract #600]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California.
 348:Burger DM, Droste JAH, Kearney BP, et al. Lack of clinically relevant drug-drug interaction between tenofovir DF and rifampin in healthy volunteers [abstract TuPeB4623]. XV International AIDS Conference; 2004 July 11-16; Bangkok, Thailand.
 349:Droste JA, Verweij-van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 680-4.
 367:Kearney BP, Isaacson E, Sayre J, et al. Tenofovir DF and oral contraceptives: lack of a pharmacokinetic drug interaction [abstract #A-1618]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.
 391:Baraclude [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2005.
 429:Scholler-Gyure M, Debroye C, Woodfall B, et al . Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate [poster A-371]. Poster presentation at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-“30, 2006.
 430:Kearney BP and Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacother 2009; 29: 924-29.
 443:Gruber VA, Baker J, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir [abstract A1-1306]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California.
 567:Edurant [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; May 2011.
 569:Victrelis [package insert]. Whitehouse Station, NJ: Schering Corporation; May 2011.
 571:Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals Inc; May 2011.
 641:Tivicay [package insert]. Research Triangle Park, NC: Viiv Healthcare; Sept 2013.
 659:Sovaldi [package insert]. Foster City, CA: Gilead Sciences; 2013.
 679:Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2013.
 713:Harvoni [package insert]. Foster City,CA: Gilead Sciences; 2016.
 727:Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
 747:Daklinza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2016
 755:Evotaz [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2017.